0001650664-24-000013.txt : 20240305 0001650664-24-000013.hdr.sgml : 20240305 20240305195442 ACCESSION NUMBER: 0001650664-24-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240302 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mei Baisong CENTRAL INDEX KEY: 0001938499 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37687 FILM NUMBER: 24723734 MAIL ADDRESS: STREET 1: C/O EDITAS MEDICINE, INC. STREET 2: 1 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Editas Medicine, Inc. CENTRAL INDEX KEY: 0001650664 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464097528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-401-9000 MAIL ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 wk-form4_1709686469.xml FORM 4 X0508 4 2024-03-02 0 0001650664 Editas Medicine, Inc. EDIT 0001938499 Mei Baisong C/O EDITAS MEDICINE, INC. 11 HURLEY ST. CAMBRIDGE MA 02141 0 1 0 0 SVP, CHIEF MEDICAL OFFICER 1 Common Stock 2024-03-02 4 A 0 50900 0 A 122955 D Common Stock 2024-03-02 4 A 0 19458 0 A 142413 D Common Stock 2024-03-02 4 A 0 19457 0 A 161870 D Common Stock 2024-03-04 4 S 0 20327 9.4173 D 141543 D Stock Option (right to buy) 10.53 2024-03-02 4 A 0 152800 0 A 2034-03-01 Common Stock 152800 152800 D The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028. Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022. Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022 and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028. /s/ Baisong Mei 2024-03-05